CD274 and cancer: In the CHECKMATE‐026 trial, patients administered nivolumab with high TMB and PD‐L1 expression ≥ 50% had a higher response rate than patients with high TMB or PD‐L1 expression ≥ 50% administered other treatment (75% vs. 32% vs. 34%).12 In KEYNOTE‐028, a study of pembrolizumab treatment across 20 cancer types, higher T‐cell‐inflamed gene‐expression profile (GEP), PD‐L1 expression, and/or TMB were associated with higher response rates and longer PFS.